An interventional study of Hearticellgram-AMI in Acute Myocardial Infarction, sponsored by Pharmicell Co., Ltd.. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Pharmicell Co., Ltd. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 57th largest by planned enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2022, is one of 18 with no phase, reaches primary completion later than 15 of the 25 other live ones, and was the 91st registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
CHA University · Sites in Korea, Republic of
Ages 18+
Seoul National Hospital · Sites in Korea, Republic of
Ages 19–80
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 25 · Phase 4 22
First in 2001; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 820 across the 73 interventional studies, 1,537 across the 25 observational. Of the 55 that completed or were terminated, 14 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 99 have an industry lead sponsor. The 10 most frequent:
Pharmicell Co., Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Pharmicell Co., Ltd. has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT03412435Seung-Jung ParkAsan Medical Center Myocardial Infarction Registry | 2026-12-31 |
| NCT04755387Dong-A UniversityTicagrelor De-escalation Strategy in AMI Patients | 2027-01-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Patients with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
Biological: Hearticellgram-AMI
Patients who had administered Hearticellgram-AMI.
Rate of AESI
death, neoplasms or malignancies in tissues or organs, Immune response
Time frame: For 5 years
Started Mar 2022 (actual). Primary completion is estimated for Oct 2028, 79 months after the start.
Of 33 industry-sponsored interventional studies with no phase under Myocardial Infarction, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 79 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pharmicell Co., Ltd.